AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24241487 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 497
Study 24241487 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX
Number of subjects: 497
Study 22527828 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BK)
Number of subjects: 107
Study 22527828 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 107
Study 20015605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-responsive treatment (GRT) program using manualized curricula (Helping Women Recover and Beyond Trauma)
Number of subjects: 115
Study 20015605 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-responsive treatment (GRT) program
Number of subjects: 115
Study 20015605 — intervention group
Group type: COMPARATOR
Intervention: Standard prison-based therapeutic community
Number of subjects: 115
Study 18081834 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 microg kg(-1) rFVIIa
Number of subjects: 0
Study 18081834 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg kg(-1) rFVIIa (administered at hours 0, 3, and 6)
Number of subjects: 0
Study 18081834 — intervention group
Group type: COMPARATOR
Intervention: APCC (75 U kg(-1) at hour 0)
Number of subjects: 0
Study 18081834 — intervention group
Group type: EXPERIMENTAL
Intervention: Global response algorithm
Number of subjects: 0
Study 15879805 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 78
Study 15879805 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 78
Study 12208434 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with remifentanil and propofol
Number of subjects: 50
Study 12208434 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl anesthesia (SF)
Number of subjects: 50
Study 11428976 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg qid for 12 weeks)
Number of subjects: 55
Study 8701375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with omeprazole and bismuth
Number of subjects: 44
Study 8701375 — intervention group
Group type: COMPARATOR
Intervention: Placebo with omeprazole and bismuth
Number of subjects: 44
Study 1837113 — intervention group
Group type: EXPERIMENTAL
Intervention: CB006 (0.4 mg/kg)
Number of subjects: 14
Study 1837113 — intervention group
Group type: EXPERIMENTAL
Intervention: CB006 (2 mg/kg)
Number of subjects: 14
Study 1837113 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (19 patients)
Number of subjects: 14
Study 6228938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate (DHT) 1.5 mg t.i.d.
Number of subjects: 559
Study 6228938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 30692255 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 25
Study 30692255 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin plus LSD
Number of subjects: 25
Study 29762690 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment in HIV‐1‐positive infants
Number of subjects: 109
Study 29762690 — intervention group
Group type: COMPARATOR
Intervention: HEU infants (control)
Number of subjects: 109
Study 26721782 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (1-time, 1 hour yoga class with a certified instructor)
Number of subjects: 52
Study 26721782 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (1-time, 1 hour PowerPoint presentation by an obstetrician)
Number of subjects: 52
Study 26721782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Yoga and Control)
Number of subjects: 52
Study 25164700 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir plus peginterferon/ribavirin (simeprevir/PR)
Number of subjects: 848
Study 25164700 — intervention group
Group type: COMPARATOR
Intervention: placebo plus peginterferon/ribavirin (placebo/PR)
Number of subjects: 848
Study 22209388 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC+I (8 individual motivational enhancement sessions and 16 treatment readiness group sessions with monetary incentives)
Number of subjects: 281
Study 22209388 — intervention group
Group type: COMPARATOR
Intervention: MRC-only (8 individual motivational enhancement sessions and 16 treatment readiness group sessions)
Number of subjects: 281
Study 22209388 — intervention group
Group type: COMPARATOR
Intervention: SRC (standard referral)
Number of subjects: 281
Study 19114223 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-cupping care
Number of subjects: 98
Study 19114223 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study 17767458 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 2
Study 15688691 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nuan Gan Jian Jiao Nang (MNGJ)
Number of subjects: 66
Study 15688691 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 12470747 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral expansion band (SEB) segments
Number of subjects: 29
Study 12470747 — intervention group
Group type: COMPARATOR
Intervention: Control eye (nonoperated)
Number of subjects: 29
Study 9801679 — intervention group
Group type: EXPERIMENTAL
Intervention: TruPulse laser (Tissue Technologies, Palomar Medical Products Inc, Lexington, Mass)
Number of subjects: 35
Study 9801679 — intervention group
Group type: COMPARATOR
Intervention: UltraPulse 5000 laser (Coherent Medical Inc, Palo Alto, Calif)
Number of subjects: 35
Study 7698680 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog (10 micrograms, 2 intravenous pulses)
Number of subjects: 29
Study 7698680 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH injection
Number of subjects: 29
Study 7698680 — intervention group
Group type: COMPARATOR
Intervention: LH secretion
Number of subjects: 29
Study 7698680 — intervention group
Group type: COMPARATOR
Intervention: FSH secretion
Number of subjects: 29
Study 2668148 — intervention group
Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon (5 million units per m2 three times per week for 6 months)
Number of subjects: 64
Study 2668148 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 64
Study 338136 — intervention group
Group type: EXPERIMENTAL
Intervention: MA therapy (Adriamycin + Melphalan)
Number of subjects: 40
Study 338136 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC therapy (Adriamycin + Melphalan + Cyclophosphamide)
Number of subjects: 40
Study 338136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (Cyclophosphamide + Methotrexate + 5-Fluorouracil) after induction therapy
Number of subjects: 40
Study 31146789 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bracing
Number of subjects: 0
Study 31146789 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 0
Study 27771973 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg)
Number of subjects: 46
Study 27771973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26306011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filter
Number of subjects: 0
Study 26306011 — intervention group
Group type: COMPARATOR
Intervention: Pure anticoagulation
Number of subjects: 0
Study 24279519 — intervention group
Group type: EXPERIMENTAL
Intervention: KM110329
Number of subjects: 66
Study 24279519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21126861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear carbohydrate drink (CCD) containing 50 g of carbohydrate
Number of subjects: 12
Study 21126861 — intervention group
Group type: COMPARATOR
Intervention: Drink containing 50 g of carbohydrate, 15 g of glutamine, and antioxidants (ONS)
Number of subjects: 12
Study 19638909 — intervention group
Group type: EXPERIMENTAL
Intervention: EIPL‐IPC
Number of subjects: 88
Study 19638909 — intervention group
Group type: COMPARATOR
Intervention: IPC
Number of subjects: 88
Study 19638909 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 88
Study 19681254 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 43
Study 19681254 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide custom tray (Opalescence 10%)
Number of subjects: 43
Study 15955273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulins (IVIg)
Number of subjects: 0
Study 11990976 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglass display with natural scenery (V-session)
Number of subjects: 72
Study 11990976 — intervention group
Group type: COMPARATOR
Intervention: Static blank screen eyeglass display (B-session)
Number of subjects: 72
Study 9860780 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 40 mg
Number of subjects: 886
Study 9860780 — intervention group
Group type: COMPARATOR
Intervention: tPA
Number of subjects: 886
Study 9860780 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 30 mg
Number of subjects: 886
Study 9860780 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 50 mg
Number of subjects: 886
Study 8938250 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl t-butyl ether (MTBE)
Number of subjects: 10
Study 8938250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl t-butyl ether (ETBE)
Number of subjects: 10
Study 8938250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-amyl methyl ether (TAME)
Number of subjects: 10
Study 8938250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-butyl alcohol (TBA)
Number of subjects: 10
Study 2520619 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with low sodium and high glucose concentration (Na+ 35, glucose 200 mmol/L)
Number of subjects: 116
Study 2520619 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with high sodium but low glucose concentration (Na+ 60, glucose 111 mmol/L)
Number of subjects: 116
Study 2520619 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS containing glycine and a glucose polymer (Na+ 50, glucose 50, glycine 50 mmol/L)
Number of subjects: 116
Study 2520619 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS with high glucose content
Number of subjects: 116
Study 5572682 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed polyphenol inhalation by byssinotic cardroom workers
Number of subjects: 576
Study 5572682 — intervention group
Group type: COMPARATOR
Intervention: Condensed polyphenol inhalation by normal control subjects and non-byssinotic cardroom workers
Number of subjects: 576
Study 5572682 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean titres between groups
Number of subjects: 576
Study 5572682 — intervention group
Group type: COMPARATOR
Intervention: Duration of employment in non-byssinotic cardroom workers
Number of subjects: 576
Study 5572682 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of cardroom exposure in byssinotic cardroom workers
Number of subjects: 576
Study 30900242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (n=68)
Number of subjects: 136
Study 30900242 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (n=68)
Number of subjects: 136
Study 28645986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with a therapist and Kaspar robot
Number of subjects: 40
Study 28645986 — intervention group
Group type: COMPARATOR
Intervention: Therapist only (Control)
Number of subjects: 40
Study 25631505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 40
Study 25631505 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 25631505 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 40
Study 23817340 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose (30 mg/kg)
Number of subjects: 46
Study 23817340 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose (20 mg/kg)
Number of subjects: 46
Study 21933752 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir once daily (two 400 mg tablets taken together every 24 h)
Number of subjects: 775
Study 21933752 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir twice daily (one 400 mg tablet every 12 h)
Number of subjects: 775
Study 21933752 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir once daily
Number of subjects: 775
Study 21933752 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir twice daily
Number of subjects: 775
Study 18757172 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing (QS) approach
Number of subjects: 60
Study 18757172 — intervention group
Group type: COMPARATOR
Intervention: Minimal-incision medial parapatellar (MP) approach
Number of subjects: 60
Study 15603007 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized typing training
Number of subjects: 32
Study 15603007 — intervention group
Group type: EXPERIMENTAL
Intervention: Keypad training
Number of subjects: 32
Study 10591939 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mm femoral component (group A)
Number of subjects: 60
Study 10591939 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mm femoral component (group B)
Number of subjects: 60
Study 10591939 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 60
Study 8580574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD; median 0.84 g.kg-1.day-1)
Number of subjects: 10
Study 8580574 — intervention group
Group type: COMPARATOR
Intervention: Medium-protein diet (MPD; median 1.33 g.kg-1.day-1)
Number of subjects: 10
Study 8580574 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (HPD; median 2.05 g.kg-1.day-1)
Number of subjects: 10
Study 2406856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) at a dosage of 100 mg/(kg.d) for 5 days
Number of subjects: 123
Study 2406856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 7363645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 11
Study 7363645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31926000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 (single ascending doses)
Number of subjects: 112
Study 31926000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 (multiple ascending doses for 14 days)
Number of subjects: 112
Study 31926000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 (single dose arm for PK assessment)
Number of subjects: 112
Study 31926000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 (safety assessment)
Number of subjects: 112
Study 31793540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam (hopantenic acid)
Number of subjects: 87
Study 31793540 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment and placebo
Number of subjects: 87
Study 28902065 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Regulation (ER) intervention
Number of subjects: 420
Study 28902065 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion (HP) condition
Number of subjects: 420
Study 28902065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low unsupervised time
Number of subjects: 420
Study 28902065 — intervention group
Group type: EXPERIMENTAL
Intervention: High unsupervised time
Number of subjects: 420
Study 25943669 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD (evaporative and conductive cooling)
Number of subjects: 10
Study 25943669 — intervention group
Group type: EXPERIMENTAL
Intervention: COOL (evaporative cooling)
Number of subjects: 10
Study 25943669 — intervention group
Group type: COMPARATOR
Intervention: CONT (no precooling)
Number of subjects: 10
Study 23832433 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg)
Number of subjects: 60
Study 23832433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 60
Study 23832433 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of curcumin and fluoxetine
Number of subjects: 60
Study 23832433 — intervention group
Group type: COMPARATOR
Intervention: All groups (Curcumin, Fluoxetine, Combination)
Number of subjects: 60
Study 22122292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 488
Study 22122292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 488
Study 22122292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488
Study 22122292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 488
Study 19152106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) activated (ON)
Number of subjects: 839
Study 19152106 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) inactivated (OFF)
Number of subjects: 839
Study 17803013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 405
Study 17803013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 405
Study 17803013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 15521935 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) technique
Number of subjects: 557
Study 15521935 — intervention group
Group type: COMPARATOR
Intervention: Conventional rectal cancer surgery
Number of subjects: 557
Study 11476413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of intravenous midazolam
Number of subjects: 34
Study 11476413 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 34
Study 9738557 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision plus isolated limb perfusion (ILP) with melphalan and mild hyperthermia
Number of subjects: 832
Study 9738557 — intervention group
Group type: COMPARATOR
Intervention: Wide excision only
Number of subjects: 832
Study 8036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Four vaccine doses at months M0, M1, M2 and M12
Number of subjects: 582
Study 8036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Three vaccine doses at M0, M1 and M6
Number of subjects: 582
Study 8036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Three vaccine doses at M0, M1 and M12
Number of subjects: 582
Study 8036822 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two doses
Number of subjects: 582
Study 8036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination with CHO‐recombinant vaccine
Number of subjects: 582
Study 29924719 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP group (progressive strengthening, agility training, plyometrics)
Number of subjects: 79
Study 29924719 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP + PERT group (SAP with perturbation training)
Number of subjects: 79
Study 29924719 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 79
Study 29924719 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 79
Study 27221952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime hypertension treatment strategy
Number of subjects: 18078
Study 27221952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime chronotherapy with >/=1 conventional hypertension medications
Number of subjects: 18078
Study 27221952 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine diagnosis of hypertension and individualized assessment of CVD and other risks by ABPM
Number of subjects: 18078
Study 27221952 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of CVD death, myocardial infarction, coronary revascularization, heart failure, ischemic stroke, and hemorrhagic stroke
Number of subjects: 18078
Study 24758484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with SOX (Ce-SOX)
Number of subjects: 56
Study 23782955 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0348292 (0.1 mg qd to 10 mg qd)
Number of subjects: 0
Study 23782955 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (30 mg bid)
Number of subjects: 0
Study 18996518 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in low-response patients
Number of subjects: 95
Study 18996518 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in moderate-response patients
Number of subjects: 95
Study 18996518 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum M-CSF levels in high-response patients
Number of subjects: 95
Study 18996518 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CSF levels in serum throughout stimulation until oocyte retrieval
Number of subjects: 95
Study 18996518 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CSF levels in pregnant patients post-retrieval
Number of subjects: 95
Study 18686051 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatrically based intervention (acting lessons, twice a week for 4 weeks)
Number of subjects: 122
Study 18686051 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 122
Study 18686051 — intervention group
Group type: COMPARATOR
Intervention: Singing (different performing art)
Number of subjects: 122
Study 16778272 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation (UR) plus electrostimulation (ES) for 4 weeks
Number of subjects: 17
Study 16778272 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation (UR) alone
Number of subjects: 17
Study 14760341 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d)
Number of subjects: 159
Study 14760341 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/d)
Number of subjects: 159
Study 11421145 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music of their choice via audiotapes and headphones before and during simulation and daily treatments)
Number of subjects: 42
Study 11421145 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 42
Study 11421145 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 42
Study 9204327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate
Number of subjects: 60
Study 9204327 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 7648782 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Number of subjects: 46